Analyst Reports

  • 08 Jul 2025

    Edison Investment Research update
    Actinogen Medical – XanaMIA study enrols 100th patient

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 06 Apr 2025

    Bioshares Edition 972:
    Actinogen Medical – Progressing its Phase IIb/III Alzheimer’s Study

    Actinogen Medical Limited (Company) is a Corporate Subscriber to Bioshares which prepared this report. The report solely reflects the views of Bioshares.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Bioshares at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report

Latest results

2024 Full Year Financial results

View Results Centre

2024 Annual General Meeting

Actinogen’s next Annual General Meeting

Date: 14 November 2024

Read more

Back
to top